Report Name: Alere Inc. Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation
ALERE INC. Report – Publisher: Research Cosmos
Price Scheme of the Report:
Single User License – USD 150
Team License – USD 175
Corporate License – USD 250
Alere Inc– Business Description:
Alere Inc. is engaged in developing, manufacturing and marketing of consumer and professional medical diagnostic products. The company has presence in approximately 30 countries. The company operates through three business segments: Professional Diagnostics, Consumer Diagnostics, and Other Non-Reportable. The Professional Diagnostics segment includes an array of rapid diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases. Professional diagnostics are generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors’ offices and patient self-testing. The company’s current professional diagnostic products include point-of-care and laboratory tests sold within its focus areas of infectious disease, cardiometabolic disease, and toxicology. In FY2016, the Professional Diagnostics segment reported revenues of $2,159.7 million, which accounted for 90.9% of the company’s total revenue. The Consumer Diagnostics segment consists primarily of manufacturing operations related to the company’s role as the exclusive manufacturer of products for Swiss Precision Diagnostics (SPD), its 50/50 joint venture with The Procter & Gamble Company (P&G). The segment’s consumer diagnostic products consist of its First Check brand of over-the-counter drug tests for at-home testing for up to seven illicit drugs and five prescription drugs, as well as First Check brand over-the-counter tests for cholesterol monitoring. The company markets and sells its First Check consumer drug testing products in the US through retail drug stores, drug wholesalers, groceries and mass merchandisers. In FY2016, the Consumer Diagnostics segment reported revenues of $74.2 million, which accounted for 3.1% of the company’s total revenue. Other Non-Reportable segment of the company consists of Alere Home Monitoring business. Alere Home Monitoring business offers patient self-testing services. These services support anticoagulation management through frequent self-testing by patients (using various third-party PT/INR coagulation monitors) who take warfarin to control their risk for stroke and clotting disorders. These services are designed to provide physicians with data that allow them to make decisions in real time, deliver quality care, and put the individuals they treat on a pathway to better health. Alere Home Monitoring assists patients in acquiring home INR (international normalized ratio) monitors and with insurance coverage determinations and provides physicians with a model that allows them to incorporate patient self-testing into their practices. In FY2016, the Other Non-Reportable segment reported revenues of $142.5 million, which accounted for 6% of the company’s total revenue. Geographically, the company classifies its operations into three segments, namely the US, Europe, and Elsewhere (includes, among many others, China, India, Japan, South Korea, Brazil, Canada, Uganda and Nigeria). In FY2016, the US segment accounted for 54.5% of the company’s total revenues, followed by Europe with 16.9%; and Elsewhere with 28.6%.
Scope of the Report:
About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.
Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.
Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.
Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.
Key Questions Answered
What domain does Balfour Beatty plcoperate and what are key points about it?
What is the product/service portfolio of Atea ASA.?
How has Balfour Beatty plcperformed financially from 2013?
How does Balfour Beatty plcrank among its peers in terms of revenue and market share?
What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?
What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?
What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?
Reasons to buy
Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost
12 hour delivery time fulfilling your urgent requests as per your requirement
On-demand customization options that can completely cater to your needs by focusing the report on given specifics
For More Information, Get Sample of the report:Request Sample
Got Some Questions? Inquire Here:Inquire Before Buying
Get This Report:Purchase Now
For More Details, Contact Provider Directly:
+1 888 709 8757